APP and Alzheimer disease: This study investigated the therapeutic potential of LY341495, a selective mGluR2/3 antagonist, in APP/PS1 transgenic mice, a widely used AD model.<h4>Methods</h4>Male APP/PS1 mice were treated with the selective mGluR2/3 antagonist LY341495.